The startup, Optimi Health Corp., has been granted permission by the Canadian government to export medical-use psychedelic substances to Australia. The substances include pills infused with psilocybin, derived from magic mushrooms, and MDMA, as approved by the health department.
As the demand continues to grow, not just within the local Ontario magic mushrooms market, other countries are also looking to Canada as a model for legalizing and exploring serotogenic compounds for medicinal applications.
You can confidently buy psychedelics online in Canada from trustworthy sources, unlocking your potential in the process.
[toc]Major Takeaways:
- Vancouver-based startup, Optimi Health, has been awarded a drug establishment license to export magic mushroom pills to Australia.
- In Australia, licensed psychiatrists are allowed to use magic mushrooms for treating chronic depression.
- The treatment regimen consists of three sessions, each lasting approximately eight hours, spread over five to eight weeks.
The Rise of Psilocybin Capsules in Canada
Optimi, a fledgling Vancouver-based company, plans to use its certification to spearhead the growth of the psychedelic drug pharmaceutical market and secure an early market entrant advantage.
Seven firms have exported either psilocybin, MDMA, or both, but strictly for clinical trials. A spokesperson from Canada’s health department could not confirm whether these exports were intended for regular patient use and declined to reveal the companies due to security reasons.
This accomplishment places Optimi in an exclusive international supplier group, as the current market trend favors clinical over recreational uses.
What Does the Pill Contain?
Although the company has not disclosed the specific mushroom strain used in the pill, they are known to work with various strains, including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town, with a population of around 3,000, is situated three hours east of Vancouver.
Australia and Psychedelic Mushrooms: An Intriguing Relationship
About 1 in every 5 Australians aged between 16 and 85 may experience a mental health issue. PTSD (post-traumatic stress disorder) could affect around 11% of Australians at some point in their lifetime, while anxiety disorders are prevalent in about 17% of the population.
There are many strategies for treating mental health conditions, but not all are effective for every person. Those who don’t respond to particular treatments may find it difficult to find an approach that works for them, increasing their susceptibility.
A Detailed Explanation of the Process
Australia has led the way in using psilocybin, allowing licensed psychiatrists to use this regulated substance to treat PTSD and depression resistant to traditional treatments.
In an unexpected move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic purposes. The TGA asserted that these substances are safe when used in a medically supervised setting for patients with severe mental disorders.
This shift has been transformative for numerous mental health professionals and researchers. The use of these substances will be strictly monitored; it’s not as simple as taking a pill and departing.
The typical treatment plan involves three sessions over a period of five to eight weeks. Each session lasts approximately eight hours, during which the therapist stays with the patient throughout.
The Role of Canada in Psilocybin Research
Canada has become a key location for psilocybin research, greatly expanding our understanding of this substance. Health Canada, along with various institutions, is at the forefront of investigating the therapeutic potential of psilocybin in treating diverse mental health disorders.
Research institutions are no longer required to classify these substances as illegal or rely on unauthorized dispensaries or mushroom stores. The government now permits certain institutions to grow mushrooms for research purposes.
The increased accessibility to substances previously deemed harmful allows researchers to deepen their understanding of their potential benefits to many individuals.
A Recurring Trend
This field’s potential was initially identified in the 1950s as a means to address mental health disorders and substance abuse, including alcohol dependency. The early pioneers of this research included English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer, who conducted their studies at the Weyburn Mental Hospital in Saskatchewan. Under the leadership of then-Premier Tommy Douglas, significant progress was made as he granted the medical community substantial autonomy to investigate their medical hypotheses.
Dr. Osmond and Dr. Hoffer initiated investigations with LSD, mescaline, and peyote as potential alternatives to the harsh procedures of electroshock and lobotomy. Their research expanded in unforeseen directions, with the pair suggesting doctors, nurses, and support staff experiment with these substances.
Canadian Health Research Institutes
Through the Institute of Neurosciences, Mental Health and Addiction, the Canadian Health Research Institutes are supporting three clinical trials exploring the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Facility | Lead Investigator | Project Budget |
| A controlled randomized trial | Psychological distress in terminal cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms underlying psilocybin therapy for alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a more thorough understanding of controlled substances’ benefits. The Canadian Drugs and Substances Strategy (CDSS), instigated by the Government of Canada, has made this possible.
Further Psychedelic Research
Psychiatrists in Vancouver have started a phase III clinical trial of MDMA, commonly known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The treatment includes three eight-hour sessions with MDMA, spaced a month apart, and nine 90-minute sessions without the drug. Researchers view this trial as historically important, marking the first clinical examination of an illegal drug.
This substance has been making waves as the first new psychedelic substance to come into focus in over four decades.
Getting to Know Psilocybin
Psilocybin is a psychedelic compound that naturally develops in several types of mushrooms. After ingesting the compound, it transforms into psilocin. This substance stimulates the serotonin 5-HT2a receptors present in the cortical pyramidal cells in the brain, which serve as the primary operating sites.
Local authorities are investigating the potential of this substance to help with issues such as depression, anxiety, addiction, and emotional distress at the end of one’s life, by promoting self-reflection and spiritual awareness.
Why is it Effective in Treating Depression, PTSD, and Other Conditions?
The active component acts on various parts of the brain, making it potentially beneficial for a range of mental disorders. Several patients in Canada and Australia have undergone this therapy with promising results, experiencing minor side effects such as temporary anxiety or slightly elevated blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: This compound acts as a partial agonist at serotonin receptors, particularly the 5-HT2A subtype, which plays a critical role in emotional processing and mood regulation.
- Modulation of Default Mode Network (DMN): It reduces activity in the DMN, promoting introspection, diminishing rigid thinking patterns, and enhancing emotional adaptability.
- Stimulation of Prefrontal and Limbic Areas: The antidepressant effects of this compound result from its influence on the prefrontal and limbic areas of the brain, including the amygdala. In people with depression, there is often a reduced response to emotional stimuli. This substance enhances the response to positive emotional stimuli in the right amygdala and decreases or normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: It fosters feelings of euphoria, interconnectedness, and emotional transparency during and following the experience.
- Enhanced Emotional Processing: The psychedelic journey may allow individuals to safely face and process deeply ingrained emotions, traumatic memories, or existential concerns in a supportive environment.
- Spiritual and Existential Realizations: Research from Johns Hopkins University and Imperial College London suggests that it can lead to enduring positive changes, such as enhanced wellness, increased life satisfaction, and spiritual growth.
What Products are Available at Your Local Magic Mushroom Outlets?
Wondering how this substance can impact your mental health? Explore magic mushroom stores to discover a product that aligns with your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, encourages creativity, and improves productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Enhances wellness and improves overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Increases clarity, creativity, and focus. Includes a potent combination of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
International Acceptance of Psilocybin
Canada isn’t the only nation endorsing the therapeutic use of magic mushrooms for mental health disorders. Countries like Australia are also recognizing the benefits of these hallucinogens for conditions such as depression and PTSD. They are obtaining top-quality psychedelic capsules from reputable sources. With proper supervision, patients can significantly improve their life quality. Mushroom Coffee Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Both psilocybin and MDMA have therapeutic benefits that can enhance mental health. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA promotes empathy and is beneficial in PTSD treatments. It has the potential to improve emotional processing and
Despite being categorized as a controlled substance, it has been observed to have therapeutic benefits.
Is this treatment option accessible to all Australians?
Not necessarily. In Australia, a preliminary evaluation is required to assess an individual’s eligibility for using the substance. This assessment takes into account various factors, such as pre-existing heart conditions and a history of psychosis. The treatment is exclusively available to patients who have not responded to conventional treatments for conditions like depression, anxiety, or PTSD.
What are the implications of Canada’s mushroom exports?
Canada is strategizing to become a leader in the psychedelics market, a move akin to its approach to cannabis. If successful, this will encourage more companies to produce high-quality products. As a result, Canada could potentially become a major player in the hallucinogen market, which could strengthen its economy and make treatments more accessible to other countries. It could also prevent these countries from resorting to illegal dispensaries or suppliers for their hallucinogen needs, thereby ensuring safety.
Suggested Reading:
